Compounded GLP-1/GIP is an injectable medication that may include NAD, B6, Glycine, B12, or other additives, as determined by your provider during your medical consultation based on your individual clinical needs. A provider may prescribe a compounded version when, in the provider’s clinical judgment, a commercially available product does not meet a specific patient’s documented needs. The safety and efficacy of these combinations have not been established by the FDA. The presence or absence of these components does not imply enhanced effectiveness or altered clinical outcomes. This product may only be dispensed by a 503A partner compounding pharmacy following provider authorization and a thorough medical review.
This page provides general, non-therapeutic information for educational and compliance purposes only. It does not describe intended use, therapeutic benefit, weight-related outcomes, appetite effects, or expected clinical results.
If Prescribed, Product Purchase Includes:
– Medication
– Medical provider consultation
– Syringes
– Alcohol Pads
– Program guide
Administration and Frequency:
- Subcutaneous (SQ) Injection
- As indicated by the prescribing provider
Contraindications
Compounded GLP-1/GIP injection should not be used in individuals who:
- Have a known hypersensitivity or allergy to tirzepatide or any component of the compounded formulation
- Have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Have experienced prior serious adverse reactions to GLP-1 receptor agonists or related peptides
- Have other conditions in which incretin-based therapy is contraindicated as determined by the prescribing healthcare provider
Use in pregnant or breastfeeding individuals should occur only if a licensed healthcare provider determines that potential risks and benefits have been carefully evaluated.
Warnings and Precautions
Dual incretin receptor agonists may be associated with gastrointestinal effects and other systemic reactions. Caution is advised in individuals with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, or renal impairment. Injectable administration should be performed only as prescribed and supervised by a licensed healthcare provider. Patients should inform their healthcare provider of all medical conditions, medications, and supplements prior to receiving this compounded formulation.
Potential Side Effects
Reported side effects associated with incretin-based injectable formulations may include nausea, vomiting, diarrhea, constipation, abdominal discomfort, headache, dizziness, fatigue, or injection site reactions such as redness, swelling, or irritation. Serious adverse reactions are uncommon but may occur. Patients should seek immediate medical attention if they experience severe abdominal pain, symptoms suggestive of pancreatitis, signs of a severe allergic reaction, or other unexpected systemic symptoms.
